PURPOSE: The optimal target for glycated hemoglobin (HbA1c) has not been well defined in peritoneal dialysis (PD) patients with diabetes mellitus. METHODS: The objective of our study was to examine the predictive value of predialysis and time-averaged follow-up HbA1c values on technique and patient survival in diabetic PD patients treated in the Toronto General Hospital Home Peritoneal Dialysis Unit, between January 1, 2003 and December 31, 2008 with a median follow-up period of 30±23 months. RESULTS: Ninety-one patients (mean age 64±13 years-old) were included in this retrospective study. Patients were followed between 3 and 91 months (mean duration 30±23 months). During this period, 40 patients died. We found no statistically significant correlation between baseline predialysis HbA1c values and technique and patient survival. Time-averaged follow-up HbA1c in increments<6.5%, 6.5-8%, and >8% showed no significant survival difference among groups. CONCLUSIONS: There was no significant correlation of baseline and time-averaged follow-up HbA1c values with patient and PD technique survival.
PURPOSE: The optimal target for glycated hemoglobin (HbA1c) has not been well defined in peritoneal dialysis (PD) patients with diabetes mellitus. METHODS: The objective of our study was to examine the predictive value of predialysis and time-averaged follow-up HbA1c values on technique and patient survival in diabetic PDpatients treated in the Toronto General Hospital Home Peritoneal Dialysis Unit, between January 1, 2003 and December 31, 2008 with a median follow-up period of 30±23 months. RESULTS: Ninety-one patients (mean age 64±13 years-old) were included in this retrospective study. Patients were followed between 3 and 91 months (mean duration 30±23 months). During this period, 40 patients died. We found no statistically significant correlation between baseline predialysis HbA1c values and technique and patient survival. Time-averaged follow-up HbA1c in increments<6.5%, 6.5-8%, and >8% showed no significant survival difference among groups. CONCLUSIONS: There was no significant correlation of baseline and time-averaged follow-up HbA1c values with patient and PD technique survival.
Authors: Mark E Williams; Eduardo Lacson; Weiling Wang; J Michael Lazarus; Raymond Hakim Journal: Clin J Am Soc Nephrol Date: 2010-07-29 Impact factor: 8.237
Authors: M S Wu; C C Yu; C W Yang; C H Wu; J Y Haung; J J Hong; C Y Fan Chiang; C C Huang; M L Leu Journal: Nephrol Dial Transplant Date: 1997-10 Impact factor: 5.992
Authors: Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: Philip K T Li; Bruce F Culleton; Amaury Ariza; Jun-Young Do; David W Johnson; Mauricio Sanabria; Ty R Shockley; Ken Story; Andrey Vatazin; Mauro Verrelli; Alex W Yu; Joanne M Bargman Journal: J Am Soc Nephrol Date: 2013-08-15 Impact factor: 10.121